New Data Add Weight To Edoxaban’s Case
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has released new clinical data for its novel anticoagulant edoxaban showing that the incidence of stroke and systemic embolic events (SEEs) in patients requiring reduced doses were consistent with those in patients given standard doses twice as high.